Our Research

TP-3654 (PIM Inhibitor)

TP-3654 is an investigational inhibitor of PIM kinase.1

PIM as a potential target in cancer treatment

PIM kinases are frequently overexpressed in various hematologic and solid tumors, allowing cancer cells to evade apoptosis and promoting tumor growth.2

Preclinical Activity

TP-3654 has shown activity in reducing the growth of bladder carcinoma cell lines in vitro.1 When delivered orally in preclinical models of bladder cancer, TP-3654 reduced tumor growth in vivo.1

Clinical Development

A phase 1, first-in-human, trial of oral TP-3654 is currently being conducted in patients with advanced solid tumors.

TP-3654 is an investigational agent and is not approved by the US FDA or any other regulatory authorities.

PIM=proviral integration site for Moloney murine leukemia virus.


    References:
  1. Foulks JM, Carpenter KJ, Luo B, et al. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia. 2014;16(5):403-412. 2. Mondello P, Cuzzocrea S, and Mian M. Pim kinases in hematological malignancies: where are we now and where are we going? J Hematol Oncol. 2014;7:95.